Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on ...
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated ...